

Table E1. Receptors Status and Systemic Treatment History

	Patient No.	%
Histology[#]		
ER/PR Positive	46	83.6
ER/PR Negative	9	16.4
Her2/ErbB2 Positive	18	32.7
Her2/ErbB2 Negative	37	67.3
Triple Negative	5	9.1
Medications*		
Chemotherapeutics		
Anthracyclines	36	48
Taxanes	55	73.3
Vinca Alkaloids	27	36
Cyclophosphamide	27	36
Gemcitabine	18	24
Capecitabine	39	52.0
5FU	7	9.3
Platins	10	13.3
Ixabepilone	5	6.7
Eribulin	3	4
Biologics		
Trastuzumab	18	24
Lapatinib	5	6.7
Bevacizumab	15	20.0
Hormonals		
Tamoxifen	24	32.0
Fulvestrant	13	17.3
Aromatase inhibitors	28	37.3
Leuprolide	2	2.7
Goserelin	5	6.7
Zoledronate	13	17.3

*Note.—At least one patient was treated with etoposide, kadcyła, dasatinib, cetuximab, denosumab, irinotecan, premetrexed, cyclosporine, everolimus, methotrexate (n=2).

ER, estrogen receptor; PR, progesterone receptor; 5FU, fluorouracil.

[#]Receptors status missing or unknown in n = 20 cases.

Table E2. Radiologic Response

RECIST	CR		PR		SD		PD		ORR	
	No.	%	No.	%	No.	%	No.	%	No.	%
By Patient	0	0	24	35.3	43	63.2	1	1.5	56	82.4
By Lesion	0	0	36	34.6	63	60.6	5	4.8	82	78.8

Note.—Values expressed as incidence and percent.
 CR, Complete Response; ORR, Overall Response Rate; PD, Progressive Disease; PR, Partial Response; RECIST, Response Evaluation Criteria In Solid Tumors; SD, stable disease.

Table E3. Progressive Disease

	1mo		3mo		6mo		12mo	
	Estimate (%)	95% CI	Estimate (%)	95% CI	Estimate (%)	95% CI	Estimate (%)	95% CI
Index Lesion	3.1	.78-11.84	3.1	.78-11.84	3.1	.78-11.84	10.6	2.6-38.2
Hepatic	22.7	14.1-35.4	46.6	34.2-60.9	54.6	41.2-69.1	78.2	60.9-91.6
Extrahepatic	20.6	12.5-32.9	38	26.7-52.1	61.2	46.7-76	85.5	70.3-95.3

Note.—Values expressed as incidence and percent. CI, confidence interval.